Publications by authors named "Todd Michael Cooper"
The prognosis of children with acute myeloid leukemia (AML) has improved incrementally over the last few decades. However, at relapse, overall survival (OS) is approximately 40-50% and is even lower for patients with chemo-refractory disease. Effective and less toxic therapies are urgently needed for these children.
View Article and Find Full Text PDFArticle Synopsis
- Blinatumomab is a specialized antibody treatment targeting CD19 in children with relapsed or refractory B-cell acute lymphoblastic leukemia (BCP-ALL) and was tested in a study focusing on safety, dosage, and effectiveness.
- The study included 49 children in phase I and 44 in phase II, determining a maximum-tolerated dosage of 15 µg/m/d, with a recommended starting dose of 5 µg/m/d.
- Results showed that 39% of patients achieved complete remission within the first two treatment cycles, indicating that blinatumomab could be a promising therapy for pediatric patients with this type of leukemia.